Cargando…

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data

BACKGROUND AND OBJECTIVE: Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and glucodynamics between URLi and Humalog(®) in heal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leohr, Jennifer, Dellva, Mary Anne, Carter, Kallin, LaBell, Elizabeth, Linnebjerg, Helle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585827/ https://www.ncbi.nlm.nih.gov/pubmed/34041713 http://dx.doi.org/10.1007/s40262-021-01030-0

Ejemplares similares

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
por: Leohr, Jennifer, et al.
Publicado: (2020)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
por: Home, Philip, et al.
Publicado: (2018)

Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes
por: Shiramoto, Masanari, et al.
Publicado: (2020)

Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects
por: Shiramoto, Masanari, et al.
Publicado: (2022)

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study
por: Heise, Tim, et al.
Publicado: (2020)

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study
por: Kazda, Christof, et al.
Publicado: (2021)

Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study
por: Leohr, Jennifer, et al.
Publicado: (2021)

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
por: Thrasher, James, et al.
Publicado: (2018)

Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial
por: Wadwa, R. Paul, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension
por: Bue-Valleskey, Juliana, et al.
Publicado: (2021)

Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
por: Ishii, Takahiro, et al.
Publicado: (2021)

Use of Insulin Lispro Protamine Suspension in Pregnancy
por: Lapolla, Annunziata, et al.
Publicado: (2015)

What is the value of faster acting prandial insulin? Focus on ultra rapid lispro
por: Heise, Tim, et al.
Publicado: (2022)

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
por: Klaff, Leslie, et al.
Publicado: (2020)

Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
por: Warren, Mark, et al.
Publicado: (2021)

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis
por: Jinnouchi, Hideaki, et al.
Publicado: (2020)

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog(®) in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis
por: Miura, Junnosuke, et al.
Publicado: (2020)

Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2023)

Efficacy of insulin lispro in improving glycemic control in gestational diabetes
por: Deepaklal, M.C., et al.
Publicado: (2014)

Lispro insulin and electrolyte supplementation for treatment of diabetic ketoacidosis in cats
por: Anderson, Jodie D., et al.
Publicado: (2019)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals
por: Knadler, Mary Pat, et al.
Publicado: (2016)

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargine
por: Buse, John B., et al.
Publicado: (2011)

Comparison of thrice‐daily lispro 50/50 vs thrice‐daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes
por: Yamashiro, Keiko, et al.
Publicado: (2010)

Effects of Insulin Lispro Mix 25 and Insulin Lispro Mix 50 on Postprandial Glucose Excursion in Patients with Type 2 Diabetes: A Prospective, Open-Label, Randomized Clinical Trial
por: Li, Wei, et al.
Publicado: (2018)

Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: A comparative pilot study -Results from the Jikei-EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J-EVOLVE) study
por: Nishimura, Rimei, et al.
Publicado: (2010)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Isolation and Characterization of Acetylated Derivative of Recombinant Insulin Lispro Produced in Escherichia coli
por: Szewczak, Joanna, et al.
Publicado: (2015)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
por: Tinahones, F J, et al.
Publicado: (2014)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
por: Rojas, Arturo, et al.
Publicado: (2016)

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes
por: Forst, Thomas, et al.
Publicado: (2010)

Efficacy and Safety of Intramuscular Insulin Lispro vs. Continuous Intravenous Regular Insulin for the Treatment of Dogs With Diabetic Ketoacidosis
por: Malerba, Eleonora, et al.
Publicado: (2020)

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
por: Grant, Marshall, et al.
Publicado: (2021)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial
por: Barbieri, Douglas Eugenio, et al.
Publicado: (2015)

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
por: Uy, J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rrnts75m3j0no7e6v8bk70ugg2